Archive for March, 2011


Mar 09, 2011 No Comments by

Nabi Biopharmaceuticals (Nasdaq:NABI) said yesterday that they expect final data in the first of the two NicVAX Phase III clinical trials for for the treatment of nicotine addiction in 2H 2011. Aeterna Zentaris Inc. (NASDAQ: AEZS) and Yakult Honsha Co., Ltd. announced the signing of a development, commercialization and licensing agreement for the development, registration […]

Daily News Read more

CPRX and EXEL raise cash while FOLD Pompe clinical hold lifted

Mar 08, 2011 No Comments by

Amicus Therapeutics (Nasdaq: FOLD) announced that the FDA has removed the clinical hold for the AT2220 (1-deoxynojirimycin HCI) Investigational New Drug Application (IND) for the treatment for Pompe disease. A new Phase 2 study designed to evaluate the use of AT2220 when co-administered with enzyme replacement therapy (ERT) in subjects with Pompe disease. They expect […]

Daily News Read more

RGEN fails Phase 2b bipolar depression – ANTH files shelf. ZIOP + KERX

Mar 07, 2011 No Comments by

Anthera Pharmaceuticals, Inc. (NASDAQ: ANTH) filed a mixed shelf of $75m. Keryx Biopharmaceuticals (Nasdaq: KERX) today announced that the final dataset from the Phase 3 short-term clinical trial of Zerenex (ferric citrate) for the treatment of hyperphosphatemia in end-stage renal disease patients on dialysis has been selected for oral presentation at the upcoming National Kidney […]

Daily News Read more

BPAX raises cash again, updates for SCMP ANDS ZGNX ALTH ACHN

Mar 04, 2011 No Comments

Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN) filed a mixed shelf after hours yesterday of $100m. Allos Therapeutics, Inc. (NASDAQ: ALTH) announced after hours yesterday that they had received a Special Protocol Assessment (SPA) for their Phase 3 clinical trial of FOLOTYN (pralatrexate injection) in patients with previously undiagnosed peripheral T-cell lymphoma (PTCL). The co-primary endpoints will […]

Read more


Mar 03, 2011 No Comments

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today said they are on track to submit their NDA for linaclotide for both irritable bowel syndrome with constipation (IBS-C) and chronic constipation (CC) indications in 3Q of 2011. They also intend to submit a Market Authorization Application (MAA) for linaclotide with the European Medicines Agency for the IBS-C indication […]

Read more

INSM reverse split. GTXI stops toremifene.

Mar 02, 2011 No Comments

Insmed Incorporated (Nasdaq: INSM) announced that following a postive shareholder vote, a 1:10 reverse split will be put into effect after the close of trading on March 2, 2011. A reverse split is required to keep their bid price above $1. GTx, Inc. (Nasdaq: GTXI) today announced that they have mutually agreed with Ispen to […]

Read more

Pipeline updates – VVUS ASTM NPSP MAPP CUR ARQL ZIOP QLTI. RXII raises cash:

Mar 01, 2011 No Comments

VIVUS, Inc. (Nasdaq: VVUS) gave an update after hours yesterday maintaining previous guidance of a 2Q 2011 NDA filing of avanafil for erectile dysfunction. They noted an intention to initiate retrospective observational studies on fetal outcomes within the next two months and resubmit their NDA for QNEXA for obesity by the end of 2011. RXi […]

Read more